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ABSTRACT Identifying the mechanisms responsible for the assembly of proteins into higher-order structures is fundamental
to structural biology and understanding specific disease pathways. The amyloid- (A) peptide is illustrative in this regard as
fibrillar deposits of A are characteristic of Alzheimer’s disease. Because A includes portions of the extracellular and
transmembrane domains of the amyloid precursor protein, it is crucial to understand how this peptide interacts with cell
membranes and specifically the role of membrane structure and composition on A assembly and cytotoxicity. We describe
the results of a combined circular dichroism spectroscopy, electron microscopy, and in situ tapping mode atomic force
microscopy (TMAFM) study of the interaction of soluble monomeric A with planar bilayers of total brain lipid extract. In situ
extended-duration TMAFM provided evidence of membrane disruption via fibril growth of initially monomeric A1–40 peptide
within the total brain lipid bilayers. In contrast, the truncated A1–28 peptide, which lacks the anchoring transmembrane
domain found in A1–40, self-associates within the lipid headgroups but does not undergo fibrillogenesis. These observa-
tions suggest that the fibrillogenic properties of A peptide are in part a consequence of membrane composition, peptide
sequence, and mode of assembly within the membrane.
INTRODUCTION
Amyloid- (A) peptide is derived by proteolytic process-
ing of the extracellular and transmembrane regions of the
membrane-anchored amyloid precursor protein (APP) and
has been causally linked with the formation of diffuse and
senile plaques (Esch et al., 1990; Haass et al., 1992; Masters
et al., 1985; Roher et al., 1986). The overproduction and
deposition of A are characteristics of Alzheimer’s disease,
Down’s syndrome, and hereditary cerebral hemorrhagic dis-
ease, HCWA-D (Dutch type; Cai et al., 1993; Citron et al.,
1994; Iwatsubo et al., 1995; Suzuki et al., 1994). In vivo,
A is released as a monomeric peptide (Esch et al., 1990;
Haass et al., 1992), but during normal aging or as a result of
a disease process, A self-associates into fibers that precip-
itate as plaques in the brain parenchyma. This process is
enhanced by increased peptide concentrations, altered pH,
and non-A nucleation seeds. In vitro studies have demon-
strated that synthetic A can assemble spontaneously into
-sheet-containing fibrils (Halverson et al., 1990; Kirschner
et al., 1986; Lomakin et al., 1996; Walsh et al., 1997), that
fibrillar A can induce neuritic dystrophy (Lorenzo and
Yankner, 1994; Pike et al., 1993; Simmons et al., 1993; Soto
et al., 1995), and that A-induced cellular degeneration
occurs due to stimulation of inappropriate cell signals (Behl
et al., 1994; Giulian et al., 1996; Mattson et al., 1997;
Paradis et al., 1996). These observations suggest that defin-
ing the role of A in mitigating specific disease pathways
requires careful characterization of both the biological ac-
tivity and the active conformation of the protein.
Because A bears a portion of the APP transmembrane
domain, it has been proposed that it may modulate mem-
brane function by altering the physicochemical properties of
various membrane constituents. These perturbations may
include disruption of leaflet structure, an increase in bilayer
curvature, or formation of membrane channels (Arispe et
al., 1993; Choo-Smith and Surewicz, 1997; Mason et al.,
1996, 1999; McLaurin and Chakrabartty, 1996; McLaurin et
al., 1997, 1998; Mirzabekov et al., 1994; Pillot et al., 1996,
1997; Terzi et al., 1994, 1995). Although recent studies
have demonstrated that lipids, and in particular acidic phos-
pholipids, can induce a conformational transition in A
from random to -structure, a process that enhances fibril
formation and initiates destabilization of the associated
membrane structure, the fundamental mechanisms associ-
ated with these events remain unknown (Arispe et al., 1993;
Choo-Smith and Surewicz, 1997; McLaurin and Chakrabar-
tty, 1996, 1997; McLaurin et al., 1997, 1998; Terzi et al.,
1994, 1995).
These questions prompted us to investigate the mem-
branolytic action of A peptides on planar bilayers of total
brain lipid extract by circular dichroism (CD) spectroscopy,
electron microscopy, and in situ solution tapping mode
atomic force microscopy (TFAFM). This latter technique
has proven to be a powerful approach for deciphering bio-
molecular assembly and protein structure under near-native
conditions (Hansma et al., 1994; Karrasch et al., 1994;
Mo¨ller et al., 1999), including A-fibrillogenesis (Blackley
et al., 1999; Harper et al., 1997; Kowalewski and Holtzman,
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1999; Oda et al., 1995; Roher et al., 1993, 1996; Stine et al.,
1996). We have applied TMAFM to study protein assembly
into the crystalline solid state (Yip and Ward, 1996; Yip et
al., 1998a,b, 2000), role of chemical chaperones in modu-
lating A aggregation (Yang et al., 1999), and the oriented
association of proteins at lipid interfaces (Plaskos and Yip,
2000).
The present studies provide evidence that the mechanism
of Ainduced membrane disruption is strongly dependent
on both lipid composition and peptide structure and confor-
mation. Our in situ observation by TMAFM that A fibril
formation occurs in association with the lipid bilayer only in
the presence of acidic lipids and only when the transmem-
brane domain of A is present suggests that membrane
anchoring is important for fibrillogenesis whereas amor-
phous aggregation is favored in the absence of the acidic
lipid and/or the anchoring A29–40 transmembrane do-
main. These results illustrate that peptide structure and
sequence and membrane composition dramatically influence
protein assembly (or misassembly) at membrane interfaces.
MATERIALS AND METHODS
Peptides
A128 and A140 were synthesized by solid-phase Fmoc chemistry
by the Hospital for Sick Children’s Biotechnology Centre (Toronto, On-
tario, Canada). Peptides were purified by reverse-phase HPLC on a C18
bondapak column. Peptides were initially dissolved in 0.5 ml of 100%
trifluoroacetic acid (Aldrich Chemicals, Milwakee, WI) to ensure that the
peptide remained monomeric and free of fibril seeds, diluted in distilled
H2O, and immediately lyophilized (Jao et al., 1997). Peptides were then
dissolved at 1 mg/ml in 40% trifluoroethanol (TFE, Aldrich Chemicals) in
H2O and stored at 20°C until use. Alternatively, the lyophilized peptides
were dissolved at 10 mg/ml in PBS.
Lipids
Dimyristylphosphatidylcholine (DMPC) and total brain lipid extract were
purchased from Avanti Lipids (Alabaster, AL). To prepare the bilayer
suspensions, the lipids were dried under a stream of nitrogen, lyophilized,
and resuspended in PBS (pH 7.4) at a concentration of 1 mg/ml. Lipid
suspensions were carried through five cycles of freeze-thaw in an acetone-
solid CO2 bath, which forms both bilayer and multilayer lipid sheets. The
lipid suspensions were then bath sonicated for 15–20 min to ensure
formation of vesicles.
Circular dichroism spectroscopy
CD spectra were recorded on an Aviv CD spectrometer model 62DS
(Lakewood, NJ) at 25°C. Spectra were obtained from 200–260 nm, with a
0.5-nm step, 1-nm bandwidth and 10-s collection time per step. The effects
of the lipids on peptide conformation were determined by adding an aliquot
of stock peptide solutions to lipid suspended in PBS (pH 7.4) at a 1:20 ratio
(by weight). Final peptide concentration was 10 M. CD spectra were
examined immediately after addition of A and over a 24-h time course.
The contribution of lipids to the CD signal was removed by subtracting the
lipid-only spectra (McLaurin and Chakrabartty, 1996). Spectra were de-
convoluted using Prosce (Yang et al., 1986).
Electron microscopy
A140 was incubated in the presence and absence of total brain lipid
extract bilayers at a final peptide concentration of 0.1 mg/ml. The A-to-
lipid ratio was maintained at 1:20 (by weight) matching the solutions
sampled by CD. Preformed A140 fibrils were prepared by incubating a
10 mg/ml solution of A140 for 3 days at room temperature. For
negative-stain electron microscopy, carbon-coated pioloform grids were
floated on aqueous solutions of peptides. After grids were blotted and
air-dried, the samples were stained with 1% (w/v) phosphotungstic acid.
The peptide assemblies were observed in a Hitachi 7000 electron micro-
scope operated at 75 V.
Atomic force microscopy
Solution TMAFM images were acquired on a Digital Instruments Nano-
scope IIIA MultiMode scanning probe microscope (Digital Instruments,
Santa Barbara, CA) using 120-m oxide-sharpened silicon nitride V-
shaped cantilevers installed in combination contact/tapping mode liquid
flow cell. The AFM images were acquired using the E scanning head,
which has a maximum lateral scan area of 14.6 m  14.6 m. All
imaging was performed at tip scan rates from 1.25 to 2 Hz, using cantilever
drive frequencies of8.9 kHz (Yip et al., 1996). All images were captured
as 512  512 pixel images and were low-pass filtered. Feature size and
volumes were calculated using the Digital Instruments Nanoscope software
(version 4.21) and shareware image analysis program National Institutes of
Health-Image (version 1.62). Lateral calibration of the AFM piezoscanner
was effected by resolving the crystallographic lattice of the basal plane of
freshly cleaved mica and graphite whereas the vertical calibration was
performed by measuring mica and graphite step heights in fluid. In situ
TMAFM experiments were performed by sequential addition of the solu-
tions to the AFM fluid cell. Planar bilayers were formed by directly
injecting 500 l of the 1 mg/ml lipid suspension into the AFM fluid cell,
previously sealed against a piece of freshly cleaved mica and allowing the
vesicles to fuse in situ (Plaskos and Yip, 2000). The cell was flushed with
neat buffer and reference TMAFM height and phase images acquired in
PBS (pH 7.4) to confirm formation of stable lipid bilayers. Approximately
500 l of a 0.1 mg/ml PBS solution of the peptide of interest (A140 or
A1–28) was injected directly into the AFM cell and imaging initiated 30
min after A addition.
RESULTS
Secondary structure of A in the presence of
lipid bilayers
Recognizing that A-fibrillogenesis (Halverson et al., 1990;
Lomakin et al., 1996; Walsh et al., 1997) and A-lipid
interactions (McLaurin and Chakrabartty, 1996) are depen-
dent on initial A structure, the A140 and A1–28
peptides were dissolved in 100% trifluoroacetic acid and
immediately lyophilized to ensure that they were mono-
meric, in a random conformation, and free of fibril seeds
(Jao et al., 1997). Secondary structure of A1–40 and
A1–28 in the presence and absence of lipid bilayers was
determined using CD spectroscopy (Fig. 1). Total brain
lipid extract is ideally suited for these studies as it provides
a physiologically relevant ratio of membrane components,
including acidic and neutral phospholipids, gangliosides,
cholesterol, sphingolipids, and isoprenoids. For our control
experiments, planar bilayers of the zwitterionic lipid DMPC
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were used as the interactions of A with this lipid have been
reported previously in the literature (Arispe et al., 1993;
McLaurin and Chakrabartty, 1996, 1997; McLaurin et al.,
1997, 1998; Terzi et al., 1994, 1995).
Time-course CD spectroscopy performed over a 24-h
period on A1–40 in PBS pH 7.4 revealed that the initially
randomly structured peptide, when mixed at a 1:20 peptide-
to-lipid ratio to a final peptide concentration of 10 M
underwent a partial conformational change in the presence
of total brain lipid but remained random in the presence of
DMPC vesicles (Fig. 1, A–C). In the presence of total brain
lipid vesicles, the time-course CD spectra revealed the grad-
ual development of a spectral change indicative of both
random and -structure in the A1–40 peptide (Fig. 1 B).
FIGURE 1 Circular dichroism spectra of A1–40 and A1–28 in the absence and presence of lipid. Differences in the CD spectra of A1–40 obtained
in PBS pH 7.4 (A), and in the presence of total brain lipid extract (B) and DMPC (C) at a 1:20 peptide-to-lipid ratio with a final peptide concentration of
10 M, demonstrate that upon initial mixing (F), A1–40 is random structured in the presence and absence of all lipids. Over time, however, A1–40
undergoes a conformational transition as evidenced by the altered CD spectra. In contrast, A1–28 in PBS (D) and in the presence of total brain lipid extract
(E) and DMPC (F) at a 1:20 peptide-to-lipid ratio with a final peptide concentration of 10 M were superimposable. The CD spectra were collected on
a 24-h time period with representative curves at 24 h (Œ) depicted.
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Deconvolution of CD spectra indicates a 77% random and
21% -structure in the presence of total brain lipid extract in
comparison with A40 alone, 82% random and 15%
-structure. Because CD represents an average of all species
present in solution, it is not possible to discern a single
population associated with lipid vesicles. CD measurement
accuracy is limited by the methodology used to determine
peptide concentrations. Previous studies have demonstrated
that amino acid analysis and ninhydrin techniques for pep-
tide quantitation typically lead to an underestimation of
peptide concentration by 10%, which leads to 10–20%
higher mean ellipticity values (Marquess et al., 1989). Al-
ternatively, the use of tyrosine absorbance in trifluoroetha-
nol, as is used routinely in our laboratory, is accurate within
2%, representing a more accurate and more precise method
(Marquess et al., 1989). It should also be noted that -struc-
ture is inherently underestimated by current deconvolution
programs. Nevertheless, our CD data are consistent with the
random structure A1–40 peptide undergoing a -structure
transformation upon binding to the total brain lipid vesicles.
We cannot rule out the possibility that random structured
A1–40 peptides are in fact associated with the lipid (as
well as being in solution); however, previous studies have
demonstrated that acidic lipids can induce a -structural
transition (McLaurin and Chakrabartty, 1996, 1997;
McLaurin et al., 1997, 1998; Terzi et al., 1994, 1995).
Control experiments performed with the zwitterionic lipid
DMPC revealed that the A1–40 peptide retains mostly a
random conformation, 88%, over a 24-h time period (Fig. 1
C). Time-course CD studies performed with the N-terminal
peptide A1–28 revealed that its predominantly random
structure was unchanged in the presence of total brain lipid
extract and DMPC (Fig. 1, D–F). CD spectra at 24 h were
superimposable on the spectra collected within 30 s of
mixing A1–28 with lipid vesicles.
Structural details of A-lipid interactions
The relationship between the spectroscopically observed
conformational transition of A1–40 in the presence of
total brain lipid extracts, fibril formation, and membrane
disruption is largely unknown. Although various models of
A fibril formation have been proposed, they all agree that
the -sheet regions are defined by the hydrophobic internal
residues 17–21 and C-terminal residues 29–40/42. Fibril-
logenesis is viewed as a two-step process involving a slow
lag phase associated with the thermodynamic barrier to seed
formation and fibril nucleation and a more rapid fibril
growth and aggregation stage. These phases are known to be
mediated by various factors including peptide concentra-
tion, changes in the A peptide primary sequence, pH, and
interactions with other elements that stimulate A aggrega-
tion (reviewed in McLaurin et al., 2000).
Traditionally, electron microscopy has been used to eval-
uate A fibrillar structures and peptide-lipid interactions.
However, the sample preparation requirements of negative-
stain electron microscopy are problematic due to issues
related to sample drying and staining procedures. These
limitations restrict EM interpretation to the physical char-
acteristics (shape/size) of the fibrils and rule out real-time
interpretation of aggregation kinetics. With these limitations
in mind, negative-stain electron microscopy revealed ma-
ture A1–40 fibers extending along the peripheral surface
of total brain lipid extract vesicles after a 3-day incubation
(Fig. 2 A). However, these images are acquired ex situ and
thus can provide only indirect evidence of association be-
tween the A1–40 fibers and intact vesicles. Therefore, to
study the real-time kinetics of A-lipid interactions, in situ
solution TMAFM was used.
In intermittent-contact, or tapping-mode, AFM, the scan-
ning tip is vertically oscillated during scanning, which re-
duces frictional loads on the sample and thus the potential
for sample distortion. Although TMAFM height imaging
provides details on surface topography, phase imaging mea-
sures the relative phase shift between the applied and de-
tected tip oscillation during TMAFM imaging and thus can
provide information regarding intrinsic local surface mod-
ulus and viscoelasticity (Winkler et al., 1996). In fluid, the
observed phase shift reflects differences in the amount of
energy dissipated during tip contact with the surface and
may correlate with specific adhesive interactions between
the tip and surface, with the degree of phase shift increasing
with increasing adhesion and energy dissipation (Brandsch
et al., 1997; Cleveland et al., 1998; Czajkowsky et al., 1998;
Noy et al., 1998). For our purposes, this mode of imaging
can distinguish between lipid islands and aggregated protein
patches on top of the lipid bilayers and has the potential for
identifying structurally dissimilar domains within a lipid
bilayer that may not be detectable by topographical contrast.
In situ formation of lipid bilayers within the AFM fluid
cell was accomplished by continuously imaging the fusion
of a 1 mg/ml lipid vesicle suspension onto the mica surface
(Brian and McConnell, 1984). Previous studies have shown
that supported bilayers are typically separated from the solid
support by a thin buffer film and retain many of the prop-
erties of free membranes, including lateral fluidity (Bayerl
and Bloom, 1991; Salafsky et al., 1996; Groves et al., 1997).
AFM imaging was used to monitor the deposition of lipid
vesicles from solution to the mica surface and their subse-
quent spreading and lateral fusion into molecularly flat
bilayers populated by small amorphous globules and disc-
shaped islands. We note that bilayers were not used unless
they were found to be essentially defect-free (i.e., no expo-
sure of the underlying mica) over randomly selected 50-
m2 scan areas (Fig. 3 A).
In situ TMAFM revealed A1–40 protruding 10 Å
above the smooth 40-Å-thick total brain lipid extract
bilayers, 30 min after the addition of 0.1 mg/ml A1–40
(Fig. 3 B). We were able to distinguish the A1–40 mole-
cules from the lipid globules and islands by both height and
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phase imaging as the lipid islands and globules typically
extended 35–40 Å above the underlying 40-Å-thick
bilayer whereas the phase contrast of the lipid globules and
islands was intermediate to that of the peptide and the
supporting bilayer. The lipid islands were also morpholog-
ically distinguishable from the A molecules. We attribute
the variations in phase contrast to local differences in the
energy dissipated by these structures as they interact with
the oscillating AFM tip (Winkler et al., 1996, Brandsch et
al., 1997; Cleveland et al., 1998; Czajkowsky et al., 1998;
Noy et al., 1998).
The physiological structure of A has yet to be deter-
mined as its tendency to aggregate and polymerize has
limited the use of classical techniques such as crystallogra-
phy. Previous in situ AFM imaging has determined that
two-stranded -sheet structured A142 has an approxi-
mate volume of 10,000 Å (Yang et al., 1999) and A40 has
dimensions of 1–2 nm in diameter (Walsh et al., 1997).
Alternatively, NMR studies of A1–40 and A1–28 pep-
tides have determined that the A1–28 domain is 35 Å in
length whereas the full 40-residue peptide has a length of
48 Å (Sticht et al., 1995; Talafous et al., 1994). Using
these two divergent techniques as an indicator of size, the
extent of A1–40 exposure as determined by TMAFM
suggests partial insertion of the peptide into the bilayer,
likely through the 29–40 hydrophobic domain. At 3 h after
peptide addition, small A fibers were barely visible on the
surface of or within lipid headgroups using TMAFM height
imaging (Fig. 4 A). To elucidate the presence of A fibrils,
TMAFM phase images were examined. The use of phase
imaging to differentiate lipid and fibers that appear to be in
the same plane topographically is based on local surface
differences in viscoelasticity and differential adhesive inter-
actions between the lipid and peptide with the tip. Although
not easily resolvable by topographical contrast, phase im-
aging provided evidence of A1–40 fibrils growing within
the bilayer (Fig. 4 B). Examination of the height and phase
images revealed the presence of small fibers not associated
with disrupted lipid regions. This indicates that the lipid
headgroups can initially accommodate fibril growth. Larger
fibers could be detected and appear adjacent to the initiation
of small lipid disruptions. These images represent an inter-
mediate phase in A fibrillogenesis (Fig. 4).
The gradual growth of 120–180-Å-wide A1–40 fibrils
in the bilayer was revealed by in situ TMAFM and phase
imaging performed over 24 h (Fig. 3 C). The fibrils are in
the plane of and extend parallel to the bilayer surface,
suggesting that fibril nucleation and growth occur within the
lipid headgroups (Fig. 3 C, inset). We cannot discount
lateral diffusion of A1–40 through the bilayer although we
did not observe this process on the time scale of the
TMAFM imaging (minutes). The absence of A1–40 ag-
gregates indicate that, for total brain lipid extract, A1–40
interaction with lipid domains facilitates formation of the
fibril. The lack of A aggregates suggests that off-pathway
intermediates, reported for solution-grown fibrils (Huang et
al., 2000), are not formed in the presence of total brain lipid
extract bilayers.
FIGURE 2 Negative-stain electron microscopy of A140 in the pres-
ence and absence of lipids. (A) Preparations of A1–40, in the presence of
total brain lipid extract, give rise to fibers that grow along the surface of
vesicles (arrowheads delineate lipid edges) with some apparent aggrega-
tion. (B and C) A1–40 incubation for 24 h in PBS at 0.1 mg/ml did not
cause fibril formation (B) whereas preincubation of A1–40 for 3 days at
10 mg/ml resulted in formation of long mature fibers (C). Bar, 100 nm.
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In situ TMAFM imaging revealed extensive destabiliza-
tion of the total brain lipid extract bilayer after A1–40
fibril growth had initiated (Fig. 3 C). We found no evidence
of bilayer defects before the introduction of monomeric
A1–40 (Fig. 3 A), nor did we observe any incidence of
tip-induced bilayer damage, either before or after fibril
formation. In the disrupted membrane regions, A1–40
fibrils were associated with bilayer edges and extended
across the exposed mica substrate (Fig. 3 C). Both mem-
brane-bound and exposed fibrils were branched, and the
degree of branching appeared to be greater than that re-
ported for solution-grown fibrils (Blackley et al., 1999;
Harper et al., 1997; Kowalewski and Holtzman, 1999; Oda
et al., 1995; Roher et al., 1996; Stine et al., 1996). This
FIGURE 3 In situ TMAFM height images acquired in PBS of the interaction between A1–40 and total brain lipid extract bilayers. (A) Intact defect-free
total brain lipid bilayers before the addition of A illustrate smooth bilayer surfaces (A). (B) A1–40 molecules were found partially inserted into the total
brain lipid bilayer. (C) Fibril growth initiates at these sites and fibrils grow through the bilayer resulting in excision of large membrane patches; image
acquired 15 h after B. Inset image in C reveals that the fibrils are forming within the bilayer and not only associated with membrane edges and mica surface.
(A–C) Scale bar, 2 m; (inset) scale bar, 1 m. All images are height encoded by color with the lower underlying mica substrate shown in black and the
lighter colors representing taller features.
FIGURE 4 In situ TMAFM height images acquired in PBS of the interaction between A1–40 and total brain lipid extract bilayers. Height images of
bilayers 3 h after the addition of A demonstrate barely discernable small fibrils (A), whereas the corresponding phase image distinguishes the presence
of A fibrils within the lipid (B, arrows). Comparison of the two data sets demonstrates small A fibrils in the bilayer in the absence and presence of small
bilayer defects. Scale bar; 200 nm.
1364 Yip and McLaurin
Biophysical Journal 80(3) 1359–1371
increased branching may result from growing fibrils en-
countering membrane patches that are energetically imper-
meable to fiber growth, either due to specific lipid compo-
sition or tighter packing of the lipid headgroups. To rule out
tip interference over the time course of our experiment,
randomly chosen scan areas were examined. Although mas-
sive membrane disruption was detected after 15 h, less
disrupted areas also were present (Fig. 5 A). High-resolution
phase imaging of the less disrupted areas revealed small A
fibers within the intact bilayer headgroups in regions that
were not associated with bilayer defects (Fig. 5 B).
We considered the possibility that the fibrils we observed
were a consequence of solution fibril growth and deposition
to the bilayer surface. To address this concern, the same 0.1
mg/ml A1–40 solution used in the bilayer studies was left
to incubate at room temperature while we conducted our
bilayer studies. In situ TMAFM imaging and negative-stain
electron microscopy performed on aliquots of this solution
after 24 h did not reveal any fibrillar aggregates although
small peptide monomers or oligomers were found (Figs. 2 B
and 5 C). These observations would suggest that fibril
nucleation is facilitated by the lipid bilayer and that the
structures observed by in situ TMAFM are in fact not due to
fibril formation in the surrounding fluid.
We propose that by displacing lipid from the bilayer as it
forms, the growing fibril weakens the stabilizing lipid-lipid
lateral interactions within the bilayer and initiates the re-
lease of small bilayer patches. We did on occasion find
small fibrils that were not associated with a particular bi-
layer edge or that appeared to extend away from a bilayer
island (data not shown). We propose that these are fibrils
left behind once the membrane patch has been destabilized
and released into the surrounding buffer.
Lipid specificity of A interactions
To investigate the role of lipid composition in A-induced
membrane disruption, planar DMPC bilayers were em-
ployed as model substrates. As described above, AFM im-
aging was used to monitor the fusion of lipid vesicles onto
the mica and subsequent spreading to form an intact bilayer.
Bilayers were not used unless they were found to be essen-
tially defect-free over randomly selected scan areas. In situ
TMAFM imaging revealed A1–40 extending 12–25 Å
above the DMPC bilayer surface (Fig. 6 A). A1–40 was
typically located adjacent to small 20-Å-wide holes, sug-
gesting that the insertion process facilitated local disruption
of the bilayer. These holes extend through the bilayer to
expose the underlying mica substrate. TMAFM imaging
performed over a 15-h time period revealed the gradual
expansion of irregular patches of A1–40 aggregates
throughout the DMPC bilayer (Fig. 6 B). Initially, we found
no evidence of the A1–40 peptide on the exposed mica
surfaces or within the bilayer holes, which suggests that the
peptide prefers to self-associate or associate with the zwit-
terionic lipid. In these patches, the A1–40 aggregates
protrude up to 100 Å above the bilayer surface, not only
indicating that A1–40 interacts with the bilayer but also
confirming self-association (Fig. 6 B). In contrast to our
total brain lipid extract studies, only globular aggregate
masses of A1–40 were found in the DMPC bilayers; no
fibrils formed over a 24-h time period. These results suggest
that the critical step in membrane destabilization is A1–40
self-assembly into fibers and aggregates on the bilayer
surface.
This model was examined by studying the interaction of
preformed A1–40 fibrils or aggregates with planar bilay-
ers (Fig. 6). Negative-stain EM demonstrated that fibrils
FIGURE 5 In situ TMAFM height and phase imaging of A1–40 interactions with total brain lipid planar bilayers. (A) Height images reveal A1–40
fibrils growing through the bilayer, which results in membrane perturbations. (B) The use of phase imaging reveals A fibrils growing within the bilayer
not associated with membrane disruptions that do not exhibit topographical changes as detected by height imaging (arrows). These results demonstrate that
initially A fibrils may be accommodated within the lipid headgroups. (C) A1–40 solution examined at 24 h fails to demonstrate the presence of A
fibrils, suggesting that fibrils are not formed in solution and subsequently associate with the bilayer. Scale bars, 200 nm.
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formed by incubation of A140 at 10 mg/ml for 3 days
had the characteristic amyloid fibrillar structure (Fig. 2 C).
To examine the effects of both protofibril and aggregates on
the stability of the planar bilayers, we examined A140
after short and long incubation periods. On total brain lipid
extract bilayers, small preformed A1–40 fibrils formed
after short incubation were found on the bilayer surface but
did not extend into, or disrupt, the bilayers (Fig. 6 C). The
fibers detected by TMAFM extended 20–30 Å above the
bilayer surface. Upon interaction with the bilayer, all fibrils
appeared to circle back on themselves to form enclosed
ring-type structures rather than the extended fibrils detected
in the absence of lipid. These dimensions and fibril charac-
teristics are similar to those previously examined by AFM
in the presence of synthetic phosphatidylethanolamine and
phosphatidylserine vesicles (Lin et al., 1999). Even after
24 h of incubation, both the A fibrils and the bilayer
remained intact. Additional incubation of these fibrils re-
sults in lateral aggregation into large A masses in which
individual fibers are not readily distinguishable. Addition of
these aggregates onto the bilayer surface results in massive
peptide aggregates extending 50–100 Å above the bilayer
but does not result in bilayer disruption (Fig. 6 D). These
results reinforce our proposal that self-assembly of A on the
surface of the bilayer is critical for membrane disruption.
A sequence requirements for
membrane disruption
To investigate the relationship between A sequence and
the extent of membrane insertion, we examined the propen-
sity of A1–28, the extracellular domain of A, to induce
membrane disruption. A1–28 lacks the hydrophobic C-
terminal domain of A1–40 but still assembles into -sheet
fibrils, with the conversion between -helix, random coil,
and -structure in A1–28 being highly dependent on so-
lution conditions (Barrow and Zagorski, 1991; Brooksbank
and Marinez, 1989; Fletcher and Keire, 1997). TMAFM
height and phase imaging revealed aggregation of A1–28
on both total brain lipid and DMPC bilayers (Fig. 7). In both
cases, extended duration TMAFM indicated that membrane
destabilization resulted from lateral expansion of aggre-
gated A1–28 patches on the bilayer. DMPC bilayers
formed within the AFM fluid cell demonstrate random
membrane defects and a few lipid globules sitting on the
FIGURE 6 In situ TMAFM images
acquired in PBS of the interaction of
A1–40 with DMPC bilayers. Intact
DMPC bilayers are smooth, essen-
tially defect free, before the addition
of peptide. (A) In the presence of
DMPC bilayers, the A140 peptide
partially inserts into the bilayer. (B)
Extended duration in situ TMAFM re-
veals the gradual growth and lateral
aggregation of A140 within the
DMPC bilayers, which results in min-
imal bilayer disruption. TMAFM im-
ages acquired in PBS of the interac-
tion of preformed A1–40 fibrils with
total brain lipid extract bilayers. (C)
After the addition of small preformed
fibrils, A can be detected above the
surface of the bilayer in the absence of
membrane disruptions. (D) Large ag-
gregate A masses can also be de-
tected on intact bilayers, even after
extensive incubation. Scale bars, 200
nm (A and B) and 100 nm (C and D).
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surface of the bilayer (Fig. 7 A). The lipid globules can be
distinguished from peptide using both height and phase
imaging. At initial time points, small aggregates of A1–28
were associated with membrane holes of varying size or on
the surface of the bilayer (Fig. 7 B). As in our results with
the A1–40 peptide, the absence of obvious aggregates on
the exposed mica surface demonstrates that the peptide
prefers to associate with the lipid bilayer. The amount of
peptide associated with the bilayer could not be directly
correlated with the size of the hole, although membrane
defects did not form in the absence of peptide (Fig. 7 C).
Similar results wherein the extent of membrane disruption
cannot be directly correlated to the extent of the perturba-
tion have been observed for other bilayer systems and been
described as spinodal decomposition (Sackman and Feder,
1995; Tsai and Torkelson, 1989). Phase imaging confirmed
the presence of A peptide at the bilayer edges and dem-
onstrated the association of A with pre-existing A aggre-
gates, suggesting that A-A interactions increase with
time (Fig. 7 D). Because membrane destabilization occurred
in the complete absence of fibril formation, we propose that
self-aggregation of A at the lipid surface is sufficient to
cause local disruptions in membrane integrity.
DISCUSSION
Our CD and in situ TMAFM investigations of A-lipid
interactions have revealed that A membranolytic action
depends on A structure and lipid environment. Our obser-
vations by in situ TMAFM that suggests that A1–40
undergoes partial insertion into lipid membranes contradicts
previous x-ray diffraction and fluorescence data that re-
ported complete A1–40 insertion into the hydrocarbon
region of the bilayer (Mason et al., 1996, 1999; Mirzabekov
et al., 1994; Pillot et al., 1996). However, in contrast to our
approach where monomeric A1–40 was added to pre-
formed lipid bilayers, these earlier studies were performed
on lipid bilayers prepared in the presence of A. Energeti-
cally, preparing lipid bilayers by the latter method favors
burying the hydrophobic A peptide within the lipid acyl
chains to generate a stable bilayer structure. Moreover,
because it is known that in vivo the A peptide is released
in a monomeric form, it is therefore appropriate to investi-
gate how the freely soluble peptide will interact with mem-
brane-mimetic surfaces under analogous conditions (Esch et
al., 1990; Haass et al., 1992).
Previous studies have demonstrated that acidic phospho-
lipids and phosphoinositides promote a conformational tran-
FIGURE 7 In situ TMAFM images ac-
quired in PBS of the interaction between
A1–28 and DMPC bilayers. The initial
DMPC bilayer was smooth with minimal
bilayer defects (A). (B) Patches of A1–28
peptide (1) can be seen aggregating on the
surface of the DMPC bilayers (2) 30 min
after introduction of the A1–28 protein
solution. (C and D) TMAFM height (C)
and phase (D) images of the DMPC bilay-
ers 15 h after introduction of A1–28. The
DMPC bilayer is extensively disrupted and
large patches of A1–28 (1) are evident on
the surface of the remaining bilayer regions
(2). The phase image shown in D provides
definition of A1–28 patches seen in C.
Regions marked 3 denote the bare mica
surface. (A–D) Scale bar, 800 nm. (A–C)
Images are height encoded by color with
the lower underlying mica shown in black.
In this scheme, the lighter colored regions
represent the 12–25-Å-thick A1–28
patches residing on top of the 40-Å-thick
bilayer. Superposition of the height and
phase-contrast images revealed direct cor-
respondence between the dark regions on
the phase image, indicative of increased
adhesion and energy dissipation, with the
regions identified as A1–28 aggregates on
the lipid surface.
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sition in A from random to -structure (Arispe et al., 1993;
Choo-Smith and Surewicz, 1997; Mason et al., 1996; 1999;
McLaurin and Chakrabartty, 1996, 1997; McLaurin et al.,
1997, 1998; Mirzabekov et al., 1994; Pillot et al., 1996;
Terzi et al., 1994, 1995). We now have evidence suggesting
that this lipid-induced conformational transition is facili-
tated by A’s C-terminal hydrophobic domain. By forming
a -sheet scaffold structure, the sterically compact A pep-
tide can reside within or on the surface of the lipid head-
groups and self-associate to form the critical fibril nucleus.
After nucleation, fibril growth through the lipid bilayer
ultimately results in destabilization of the membrane
through excision of bilayer regions (Fig. 7). These results
are in agreement with Kremer and colleagues (2000), who
reported that A-induced changes in membrane fluidity
were dependent on insertion of A into the fatty acyl chains
of the bilayer. In the absence of acidic lipids or a C-terminal
hydrophobic domain, A fibril formation is abolished; how-
ever, membrane disruption still occurs via expansion of
aggregated A through the bilayer. Our observation that
aggregation of the truncated A1–28 peptide occurred on
the total brain lipid and DMPC. Comparison of the lateral
size and thickness of the aggregated A1–28 patches on the
total brain lipid bilayers with those found on the neutral
DMPC bilayers demonstrate that patches on total brain lipid
bilayers were smaller laterally but thicker than those found
on the DMPC bilayers. We attribute these observations to
preferential binding of A1–28 to small, possibly acidic,
lipid domains within the heterogeneous total brain lipid
bilayers followed by A1–28 self-association within these
domains. Based on these observations, we propose that the
steric bulk of randomly structured A peptide cannot be
readily accommodated by the lipid headgroups and gradual
enlargement of the A1–28 patches facilitates local disrup-
tion of the bilayers (Fig. 8).
Based on our observations, we propose the following
two-stage model for the membranolytic action of A. As-
sembly of A leads to highly localized disruption of the
membrane. This disruption may enable ions to pass freely
between the intra- and extracellular space and is consistent
with reports that A enhances ion fluxes, thereby altering
cellular homeostasis (Arispe et al., 1993; Mirzabekov et al.,
1994). Increasing accumulation of A and the initiation of
fibril formation through the membrane results in destabili-
zation of larger regions of the membrane. These openings
may facilitate the passage of proteins, as has been demon-
strated for endosomal-lysosomal vesicles, resulting in the
protein compartmentalization errors characteristic of Alz-
heimer’s disease (Avdulov et al., 1997; Blanc et al., 1997;
Cataldo et al., 1996; Yang et al., 1998). The presence of cell
FIGURE 8 Schematic model of the interaction between A peptides and lipid bilayers. Initial A-lipid bilayer interaction, either through insertion of the
hydrophobic domain or surface interaction with the lipid headgroups (peptide indicated in black), is readily accommodated. In the presence of acidic lipid,
fibril formation occurs as a result of a lipid-induced structural transition (total lipid pathway). Fibril growth occurs through the bilayer resulting in
displacement of lipid and eventual excision of large regions of the bilayer. In the absence of acidic lipid, fibril formation is abolished and A aggregation
occurs (DMPC pathway). This process leads to disruption of the lipid headgroups and localized destabilization of the bilayer. Small bilayer defects are
formed adjacent to small A aggregates. Growth of the A aggregates is accompanied by an increasing localized bilayer disruption and lateral expansion
of the bilayer defect.
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surface fibril formation was eloquently demonstrated on
cerebrovascular smooth muscle cells using EM (Van Nos-
trand et al., 1998), and plasma-membrane-bound A is the
initiation site for deposition of diffuse plaques (Yamaguchi
et al., 2000). Finally, the inability of preformed A fibrils to
induce membrane disruption correlates well with the lack of
in vitro toxicity observed when neuronal and cerebrovascu-
lar smooth muscle cells are incubated with preformed A
fibrils (Davis-Salinas and Van Nostrand, 1995; May et al.,
1992). Recent studies detailing the importance of the C-
terminal region of A for its neurotoxic properties have
demonstrated that nonfibrillar A induces an apoptotic
death in neurons whereas aggregated A induces a necrotic
death (Pillot et al., 1999). Our TMAFM studies have pro-
vided structural evidence of how these processes may take
place and, in particular, how membrane disruption can be
triggered by alternate structures of the same peptide. This
and related approaches to studying protein assembly (or
misassembly) at membrane interfaces will facilitate real-
time investigations of the mechanisms by which specific
protein-lipid interactions are driven by either sequence,
structure, or compositional differences and will be of par-
ticular applicability for investigating other amyloidogenic
pathways.
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